-+ 0.00%
-+ 0.00%
-+ 0.00%

HELUS PHARMA: CONTINUE TO EXPECT TOPLINE RESULTS FROM APPROACH STUDY IN Q4 OF 2026

Reuters·11/16/2026 11:00:01

Please log in to view news